The combination of THZ1 and EGFR-targeted CAR-T cells exhibit a better ability to inhibit immune resistance and prevent tumor proliferation and metastasis processes compared to applying to CAR-T cells alone in TNBC tumor models (118). Here, EGFR is linked to neoplasm.